XTNT - Earnings announcements

Raises full-year 2026 revenue guidance to a range of $101-$105 millionSignificantly strengthens balance sheetEnters into exclusive U.S. distribution agreement for Dilon Technologies' HEMOBLAST® Bellows product for high-performance hemostasis; hires Dilon's U.S. sales teamBELGRADE, Mont., May 13, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today reported financial and operating results for the first quarter ended March 31, 2026. First Quarter 2026 Financial Hi

BELGRADE, Mont., May 7, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today announced that it will release its financial results for the first quarter ended March 31, 2026, before the start of trading on Wednesday, May 13, 2026. Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host a conference call at 8:30 AM ET on that day. Conference Details:Conference Date: Wednesday, May 13, 2026Conference Time: 8:30 AM ETC

Full year 2025 revenue totals $133.9 million, an increase of 14% year-over-yearXtant delivers positive net income, adjusted EBITDA and operating cash flowTotal cash of $17.3 million as of December 31, 2025 with an additional $10.5 million received subsequent to year end related to divestitureBELGRADE, Mont., March 31, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today reported financial and operating results for the fourth quarter and full-year ended December 31, 2025.

BELGRADE, Mont., March 25, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2025, before the start of trading on Tuesday, March 31, 2026. Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host a conference call at 8:30 AM ET on that day. Conference Details:Conference Date: Tuesday, March 31, 2026Confere

Total Revenue of $33.3 Million Increased 19% Year-over-Year Delivers Positive Net Income, Adjusted EBITDA and Operating Cash Flow Reiterates FY25 Revenue Guidance of $131-$135 Million, Representing Growth of 11%-15% over FY24 Previously Announced Sale of Certain Hardware Assets and OUS Businesses to Companion Spine Anticipated to Close by Year-End BELGRADE, Mont., Nov. 10, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today reported financial and operating results for the third quarter ended September 30, 2025.

BELGRADE, Mont., Nov. 4, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and woundcare disorders, today announced that it will release its financial results for the third quarter ended September 30, 2025, before the start of trading on Tuesday, November 11, 2025. Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial officer, will host a conference call at 8:30am ET on that day. Conference Details: Conference Date: Tuesday, Nov

Total Revenue of $35.4 Million Increased 18% Year-over-Year Delivers Positive Net Income, Adjusted EBITDA and Operating Cash Flow Raises FY25 Revenue Guidance to $131-$135 Million, Representing Growth of 11%-15% over FY24 BELGRADE, Mont., Aug. 12, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and woundcare disorders, today reported financial and operating results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Highlights Revenue

BELGRADE, Mont., Aug. 5, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and woundcare disorders, today announced that it will release its financial results for the second quarter ended June 30, 2025, before the start of trading on Tuesday, August 12, 2025. Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial officer, will host a conference call at 8:30am ET on that day. Conference Details: Conference Date: Tuesday, August 12

Transaction expected to facilitate enhanced focus on Xtant's core businesses Total consideration of approximately $19.2 million allows Xtant to reduce outstanding debt and improve liquidity BELGRADE, Mont., July 8, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and woundcare disorders, today announced that the company has entered into agreements to sell certain Coflex® and CoFix® interlaminar stabilization implant assets and all OUS entities of Paradigm Spine GmbH, to Companion Spine, LLC, a French-American company fully dedicated to posterior dynamic spine stabilizatio

Revenue Increases 18% Year-over-Year Delivers Positive Net Income and $1.3 Million in Operating Cash Flow Increases 2025 Revenue Guidance to $127 Million to $131 Million BELGRADE, Mont., May 12, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and wound care disorders, today reported financial and operating results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Highlights Revenue of $32.9 million, up 18%, compared to the prior year quarterGross margin of 61.5% compared to 62.1% for the prior year quarterNet income of $58,000 compared to a net lo

BELGRADE, Mont., May 6, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic and woundcare disorders, today announced that it will release its financial results for the first quarter ended March 31, 2025, after the close of the financial markets on Monday, May 12, 2025. Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host a conference call on Monday, May 12, 2025 at 4:30 PM ET to review results. Conference Details:Conference Date: Monday, May 12, 2025Conference Time: 4:30 PM ETConference dial-in: 888-506-0062International dial

Third Quarter Revenue Growth of 12%Reaffirms Full Year 2024 Revenue Guidance of $116 Million to $120 MillionRepresenting Growth of 27% to 31% BELGRADE, MT / ACCESSWIRE / November 12, 2024 / Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the third quarter ended September 30, 2024.Third Quarter 2024 Financial HighlightsRevenue of $27.9 million, up 12%, compared to the prior year quarter; year to date revenue of $85.8 million, up 36% compared to prior year periodGross margin of 58.4% compared to 61.3% for the prior year quarterNet loss of $5.0 mi

BELGRADE, MT / ACCESSWIRE / November 7, 2024 / Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the third quarter ended September 30, 2024, after the close of the financial markets on Tuesday, November 12, 2024.Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host a conference call on Tuesday, November 12, 2024 at 4:30 PM ET to review results.Conference Details:Conference Date: Tuesday, November 12, 2024Conference Time: 4:30 PM ETConference dial-in: 888-999-3182International dial-in:

BELGRADE, MT / ACCESSWIRE / August 8, 2024 / Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the second quarter ended June 30, 2024, after the close of the financial markets on Thursday, August 8, 2024.Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host a conference call on Friday, August 9, 2024, at 9:00 AM ET to review results.Conference Details:Conference Date: Friday, August 9, 2024Conference Time: 9:00 AM ETConference dial-in: 888-999-3182International dial-in: 848-280-6330Pas

BELGRADE, MT / ACCESSWIRE / August 8, 2024 / Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the second quarter ended June 30, 2024.Second Quarter 2024 Financial HighlightsRevenue of $29.9 million, up 48%, compared to the prior year quarterGross margin of 62.1%, up 50 basis points, compared to the prior year quarterNet loss of $3.9 million compared to $2.2 million in the year ago quarterPositive Adjusted EBITDA; Adjusted EBITDA of $0.5 million compared to $0.1 million in the prior year quarterRecent Business HighlightsRecently launched two new

Expects Revenue for Full Year 2024 of $116 Million to $120 MillionBELGRADE, MT / ACCESSWIRE / May 15, 2024 / Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the first quarter ended March 31, 2024.First Quarter 2024 Financial HighlightsRevenue of $27.9 million, up 55%, compared to the prior year quarterGross margin of 62.1%, up 340 basis points, compared to the prior year quarterNet loss of $4.4 million compared to $2.1 million in the year ago quarterPositive Adjusted EBITDA; Adjusted EBITDA of $0.1 million compared to an Adjusted EBITDA loss of

BELGRADE, MO / ACCESSWIRE / May 8, 2024 / Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the first quarter ended March 31, 2024, after the close of the financial markets on Wednesday, May 15, 2024.Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host a conference call on Wednesday, May 15 at 4:30 PM ET to review results.Conference Details:Conference Date: Wednesday, May 15, 2024Conference Time: 4:30 PM ETConference dial-in: 877-545-0523International dial-in: 973-528-0016Passcode: 69

Establishes Full Year 2024 Revenue Guidance of $112 Million - $116 Million BELGRADE, Mont., April 01, 2024 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the fourth quarter and year ended December 31, 2023. "2023 was a transformative year for Xtant Medical. We achieved record annual revenues of $91.3 million, up 58% year-over-year, on which we generated organic growth of 15% compared to the prior year," said Sean Browne, President and CEO of Xtant Medical. "Additionally, we successfully integrated three separate busines

BELGRADE, Mont., March 21, 2024 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2023, before the open of the financial markets on Monday, April 1, 2024. Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host a conference call on Monday, April 1 at 9:00 AM ET to review results. Conference Details:Conference Date: Monday, April 1, 2024 - 9:00 AM ETConference dial-in: 877-407-6184International dial-in: 201-389-08

BELGRADE, Mont., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the third quarter ended September 30, 2023. "Driven by strong organic growth of 18%, and contributions from our recent acquisitions, we achieved record third quarter revenue of $25 million, an increase of 73% year-over-year, and raised our 2023 revenue guidance range for the second consecutive quarter," said Sean Browne, President and CEO of Xtant Medical. "I am extremely proud of our team's efforts integrating Surgalign's hardware and biologic

BELGRADE, Mont., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the third quarter ended September 30, 2023, before the open of the financial markets on Thursday, November 9, 2023. Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host a conference call on Thursday, November 9 at 9:00 AM ET to review results. Conference Call Details:Conference Call Date: Thursday, November 9, 2023 - 9:00 AM ETConference Call dial-in: 877-407-6184International dial

Raises 2023 Annual Revenue Guidance to $75 Million - $77 Million BELGRADE, Mont., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the second quarter ended June 30, 2023. "In the second quarter, we achieved strong revenue growth on both a sequential and annual basis driven by our core biologics and fixation businesses," said Sean Browne, President & CEO of Xtant Medical. "I am particularly pleased that we closed the quarter with positive adjusted EBITDA, which is ahead of our expectations. We ar

Acquisition to Enhance Xtant's Growing Spinal Fusion Devices Portfolio BELGRADE, Mont., July 28, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it was the successful bidder for certain assets and liabilities related to the domestic and international biologics and spinal fixation offerings of Surgalign Holdings, Inc. Xtant's initial bid, as set forth in the Asset Purchase Agreement, dated June 18, 2023, between Xtant and Surgalign, was the winning bid. "We are pleased to add these attractive assets that we anticipate will contribute to our growt

BELGRADE, Mont., July 25, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the second quarter ended June 30, 2023, before the open of the financial markets on Tuesday, August 1, 2023. Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host a conference call on Tuesday, August 1 at 9:00 AM ET to review results. Conference DetailsConference Date: Tuesday, August 1, 2023 – 9:00 AM ETConference Dial-in: 877-407-6184International Dial-in: 201-389-0877Conferen

Initiates Annual Revenue Guidance of $73 Million - $75 Million in Full Year 2023 BELGRADE, Mont., May 04, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the first quarter ended March 31, 2023. The Company also introduced financial guidance for the full year 2023. "Highlighted by solid revenue growth and the Coflex® acquisition, we are off to a strong start in 2023," said Sean Browne, President & CEO of Xtant Medical. "Guided by our strategic growth pillars, we are generating robust demand across our biologics and f

BELGRADE, Mont., April 27, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the first quarter ended March 31, 2023, before the open of the financial markets on Thursday, May 4, 2023. Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host a conference call on Thursday, May 4 at 9:00 AM ET to review results. Conference DetailsConference Call Date: Thursday, May 4, 2023 - 9:00 AM ETConference dial-in: 877-407-6184International dial-in: 201-389-0877Conference C

BELGRADE, Mont., March 07, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the fourth quarter and year ended December 31, 2022. "Highlighted by strong fourth quarter revenue results and last week's acquisition of the Coflex® product line, we are executing on our key growth initiatives," said Sean Browne, President and CEO of Xtant Medical. "We continue to generate robust demand for our biologics products, which grew 14% for the quarter, and improve our operating efficiencies by increasing our production capac

BELGRADE, Mont., March 03, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2022, before the open of the financial markets on Tuesday, March 7, 2023. Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host a conference call on Tuesday, March 7 at 9:00 AM ET to review results. Conference Details:Conference Date: Tuesday, March 7, 2023 - 9:00 AM ETConference dial-in: 877-407-6184International dial-in: 201

BELGRADE, Mont., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the third quarter ended September 30, 2022. "I am pleased that third quarter revenues increased by 5% year-over-year, led by 12% growth in our biologics business. Driven by the successful launches of our OsteoFactor™ and OsteoVive® Plus biologics products and expansion of our distribution network, we are encouraged with the trajectory of our revenue and progress to date in 2022," said Sean Browne, President and CEO of Xtant Medical. "Our team i

BELGRADE, Mont., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the third quarter ended September 30, 2022, before the open of the financial markets on Thursday, November 3, 2022. Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host a conference call on Thursday, November 3 at 9:00 AM ET to review results. Conference DetailsConference Date: Thursday, November 3, 2022 - 9:00 AM ETConference dial-in: 877-407-6184International dial-in: 201-389

BELGRADE, Mont., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the second quarter ended June 30, 2022. "We are pleased to have achieved our highest revenue quarter since the start of the pandemic. Our second quarter revenue increased 2% over the same prior year period, including 8% year-over-year growth in our biologics business, which was fueled by strong demand for our new biologics products and expansion of our distributor network," said Sean Browne, President and CEO of Xtant Medical. "On the strengt

BELGRADE, Mont., July 28, 2022 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the second quarter ended June 30, 2022, before the open of the financial markets on Thursday, August 4, 2022. Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host a conference call on Thursday, August 4 at 9:00 AM ET to review results. Conference DetailsConference Date: Thursday, August 4, 2022 - 9:00 AM ETConference Dial-in: 877-407-6184International Dial-in: 201-389-0877Conferenc

BELGRADE, Mont., May 05, 2022 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the first quarter ended March 31, 2022. "By building momentum in our business, underscored by first quarter revenue growth and the progress of our key strategic growth pillars, we are pleased with the promising start to 2022," said Sean Browne, President & CEO of Xtant Medical. "First quarter revenue increased by 3% and we achieved an impressive 13% year-over-year growth in our biologics business. Our top-line was driven by our 2021 initiative

BELGRADE, Mont., April 28, 2022 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the first quarter ended March 31, 2022, before the open of the financial markets on Thursday, May 5, 2022. Sean Browne, President and Chief Executive Officer, and Scott Neils, Interim Chief Financial Officer, will host a conference call on Thursday, May 5 at 9:00 AM ET to review results. Conference DetailsConference Date: Thursday, May 5, 2022 - 9:00 AM ETConference dial-in: 877-407-6184International dial-in: 201-389-0877Conferenc

BELGRADE, Mont., March 08, 2022 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the fourth quarter and year ended December 31, 2021. "Xtant accomplished numerous objectives in 2021 focused on developing new products, expanding our distributor network and growing our adjacent market sales that have us excited about the future of the Company," said Sean Browne, President and CEO of Xtant Medical. "Our Company achieved year-over-year revenue growth of 4%, and I am particularly pleased with the top-line performance of our bio

BELGRADE, Mont., March 01, 2022 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2021, before the open of the financial markets on Tuesday, March 8, 2022. Sean Browne, President and Chief Executive Officer, and Scott Neils, Interim Chief Financial Officer, will host a conference call on Tuesday, March 8 at 9:00 AM ET to review results. Conference DetailsConference Date: Tuesday, March 8, 2022 - 9:00 AM ETConference dial-in: 877-407-6184International dial-

BELGRADE, Mont., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the third quarter ended September 30, 2021. Third Quarter 2021 Financial Highlights: Revenue for the third quarter of 2021 totaled $13.8 million, compared to $14.0 million for the prior-year periodLoss from operations totaled $1.4 million compared to operating income of $0.8 million for the prior-year periodNet loss incurred in the third quarter of 2021 totaled $1.8 million compared to a net loss of $1.4 million for the prior-year periodNo

BELGRADE, Mont., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the third quarter ended September 30, 2021, before the open of the financial markets on Friday, November 12, 2021. Sean Browne, President and Chief Executive Officer, and Greg Jensen, Vice President, Finance and Chief Financial Officer, will host a conference call on Friday, November 12 at 9:00 AM ET to review results. Conference DetailsConference Date: Friday, November 12, 2021 - 9:00 AM ETConference dial-in: 866-682-6100Internati

BELGRADE, Mont., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the second quarter ended June 30, 2021. Second Quarter 2021 Financial Highlights: Revenue for the second quarter of 2021 totaled $15.0 million, an increase of 42% over the prior-year periodGross margin in the second quarter of 2021 was 63.5%, compared to 62.2% for the prior-year periodLoss from operations totaled $0.5 million compared to an operating loss of $0.4 million for the prior-year periodNet loss incurred in the second quarter of 2021

BELGRADE, Mont., July 29, 2021 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the second quarter ended June 30, 2021, before the open of the financial markets on Thursday, August 5, 2021. Sean Browne, President and Chief Executive Officer, and Greg Jensen, Vice President, Finance and Chief Financial Officer, will host a conference call on Thursday, August 5 at 9:00 AM ET to review results. Conference DetailsConference Date: Thursday, August 5, 2021 - 9:00 AM ETConference dial-in: 877-407-6184International di